Leveraging simulation, ANSYS aims to advance the medical industry by reducing the time taken for processes like clinical diagnostics and testing of medical apparatus. The company collaborates with medical device manufacturers, clinicians, and hospitals to develop simulation software to model how medical devices interact with the human body and understand how it behaves under set constraints or operating conditions. Following the trail of medical sciences transcending from the traditional in-vivo approach to in-vitro testing methodologies, ANSYS leads the disruption that comes in the form of in-silico testing. The FDA backed technique employs the concept of performing computational analysis on the human body to observe the functioning of body parts, medical procedures, and drugs.
The company is fostering customization of medical practices in accordance with various medical conditions. As it may be difficult or sometimes impossible to find volunteers for some of the medical procedures and tests, computation analysis lowers the costs and risks associated with traditional practices.
The simulation software developed by ANSYS allows the user to replicate tissues, bones, and implanted devices using advanced modeling techniques that are previously validated through experimentation
Owing to the fact that every human body is unique, simulations can be tailored to suit a particular condition or a specific type of body, depending on the requirements. “The current ‘one size fits all’ approach to healthcare fails to recognize the significant differences between the bodies and behaviors of different patients. This not only creates inefficiencies and cost overruns but also affects the quality of care provided. By personalizing the specific treatment to each patient, healthcare will become more affordable for patients and more profitable for providers due to increased efficiency,” adds Marchal.
Additionally, with the increasing usage of wearable and implanted devices, collecting personalized data to feed predictive models is becoming a reality. This allows healthcare providers to devise truly personalized treatment plans as well as to predict health problems before they occur. These practices foster the development of preventive medicines using statistical data and predictive analysis that will be able to detect and treat pathologies at a very early stage. According to the Avicenna Alliance, these techniques could benefit more than 50 percent of the clinical trials in the near future. While this “medical digital twin” concept might seem like science fiction, advanced technology is poised to improve the quality of life for people around the world. Marchal envisions the inevitable adoption of this in-silico approach offered by ANSYS, paving the way for virtual human laboratories to determine the uncertainties prevailing in medical sciences.
ANSYS and AVSimulation have formed a strategic partnership with an aim to accelerate the development of secure and self-governing driving for automakers.
FREMONT, CA: The recently announced partnership between AVSimulation and ANSYS aims to facilitate autonomous vehicle validation and design through virtual testing, thereby ensuring millions of miles of test drive on roads within a single week. Read More